Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma

October 22, 2019

View Press Release Corporate presentation Contact us
Previous